(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -35.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Lexicon Pharmaceuticals's revenue in 2025 is $70,864,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2025 to be $17,689,157,546, with the lowest LXRX revenue forecast at $15,780,224,280, and the highest LXRX revenue forecast at $19,498,156,175. On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $6,391,455,984, with the lowest LXRX revenue forecast at $2,142,598,617, and the highest LXRX revenue forecast at $13,736,470,104.
In 2027, LXRX is forecast to generate $9,492,336,920 in revenue, with the lowest revenue forecast at $2,241,443,058 and the highest revenue forecast at $22,703,332,533.